Acromegaly complicated with fulminant pituitary apoplexy: clinical characteristic analysis and review of literature

• Published in: Endocrine 2023-07, Vol.81 (1), p.160-167
• Main Authors: Zheng, Xue-Qing, Zhou, Xiang, Yao, Yong, Deng, Kan, You, Hui, Duan, Lian, Zhu, Hui-Juan
• Format: Article
• Language: English
• Subjects: Acromegaly; Acromegaly - drug therapy; Adenoma - surgery; Adult; Diabetes; Endocrinology; Female; Growth hormones; Humanities and Social Sciences; Humans; Insulin-like growth factor I; Insulin-like growth factors; Internal Medicine; Male; Medicine; Medicine & Public Health; Middle Aged; multidisciplinary; Original Article; Patients; Pituitary; Pituitary Apoplexy - complications; Pituitary Apoplexy - pathology; Pituitary Neoplasms - surgery; Remission; Retrospective Studies; Science; Somatostatin; Somatostatin - therapeutic use; Treatment Outcome; Young Adult
• ISSN: 1559-0100; 1355-008X; 1559-0100
• DOI: 10.1007/s12020-023-03379-7

Purpose To retrospectively summarize the clinical features of acromegaly complicated with fulminant pituitary apoplexy and analyze the prognostic factors to guide early identification and timely treatment of such patients. Methods A retrospective analysis was carried out to summarize the clinical manifestations, hormone changes, imaging, treatment and follow-up of ten patients with acromegaly complicated with fulminant pituitary apoplexy admitted to our hospital from February 2013 to September 2021. Results The mean age of the ten patients (five males and five females) at the time of pituitary apoplexy was 37.1 ± 13.4 years old. There were nine cases with sudden severe headaches and five cases with visual impairment. All patients had pituitary macroadenomas, of which six cases with Knosp grade ≥3. The level of GH/IGF-1 hormone after pituitary apoplexy was lower compared with pre-apoplexy, and 1 patient reached biochemical remission spontaneously. Seven patients underwent transsphenoidal pituitary surgery after apoplexy and one patient was treated with long-acting somatostatin analog. The biochemical remission rate was 37.5% in eight patients immediately after treatment and 50% at the last follow-up. Patients with Knosp grade ≥3 were less likely to achieve biochemical remission than those with Knosp grade